Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIPS: Linezolid for Staphylococcus Aureus Bacteraemia
NCT06958835Recruiting
- Sponsor
- University Hospital Basel
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Staphylococcus aureus bacteremia (SAB) comparing Linezolid with Placebo (2 arms). Primary endpoint: Desirability of Outcome Ranking at day 90. Started Oct 2025; status: recruiting.
02
Drugs
linezolid
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT06958835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06958835.